Table 1 Demographic, socio-economic, and clinical characteristics of C-ARDS survivors responding at follow-up
Demographic characteristics | |
Number of patients | 79 |
Age (years) | 63 (57–71) |
Sex | |
Male | 66 (84%) |
Female | 13 (16%) |
Socio-economic characteristics | |
Family unit composition | |
Single | 9 (11%) |
≥ two people | 70 (89%) |
Population of the municipality of residence | |
< 15,000 | 66 (84%) |
> 100,000 | 13 (16%) |
Employment statusa | |
Active worker | 33 (42%) |
Retired | 43 (54%) |
Monthly income (€) | |
≤ 1500 | 41 (54%) |
> 1500 | 35 (46%) |
Education | |
ISCED 0–2 | 27 (34%) |
ISCED > 2 | 51 (65%) |
Clinical characteristics | |
No preexisting comorbidities | 38 (48%) |
Preexisting comorbidities | 41 (52%) |
One comorbidity | 23 (29%) |
More than one comorbidity | 18 (23%) |
Comorbidities | |
Hypertension | 36 (46%) |
Diabetes | 9 (11%) |
Asthma and/or COPD | 10 (13%) |
Ischemic heart disease | 6 (8%) |
Neoplasm | 4 (5%) |
Chronic liver or kidney disease | |
Immunocompromised | |
BMI (kg/m2) | 27 (25–29) |
Time from symptoms to hospital admission (days) | 7 (5–10) |
SOFA score on ICU admission | 6 (4–7) |
SAPS II score on ICU admission | 27 (24–33) |
PaO2/FiO2 on ICU admission (worst) | 160 (114–225) |
Renal replacement therapy | 5 (6%) |
Prone positioning | 35 (44%) |
Hydroxychloroquine | 76 (97 %) |
Steroids | 37 (47%) |
Tocilizumab | 16 (20%) |
Tracheostomy | 22 (28%) |
Duration of ventilation (days) | 16 (12–25) |
ICU LOS (days) | 20 (13–28) |
Hospital LOS (days) | 40 (29–49) |
Laboratory data in the ICU | |
Creatinine on admission (mg/dl) | 0.92 ± 0.38 |
Creatinine max (mg/dl) | 2.00 ± 2.15 |
D-dimer on admission (μg/mL) | 2407 ± 5892 |
D-dimer max (μg/mL) | 5821 ± 9694 |
WBC on admission (10^3/mL) | 9.47 ± 4.42 |
WBC max (10^3/mL) | 17.28 ±7.6 |
CRP on admission (mg/dl) | 113 ± 81 |
CRP max (mg/dl) | 234 ± 114 |